Ankylosing spondylitis
Conditions
Interventions
Observation group:N/A
Sponsors
Hong Kong University-Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Age >= 18 years old; 2. Comply with the New York standards revised in 1984: Clinical criteria: Low back pain persists for at least 3 months and can be relieved after activity (rather than rest). (2) The movement of the lumbar vertebrae is restricted in both vertical and horizontal planes; (3) The degree of chest expansion is less than that of normal people of the same age and gender. Diagnostic criteria: Possessing unilateral grade 3-4 or bilateral grade 2-4 X-ray sacroiliitis, along with at least one of the three clinical criteria. 3. Meet the classification criteria of Axial spondyloarthritis (ASAS) in 2009: Patients with low back pain for >= 3 months and an onset age of less than 45 years (regardless of whether there are peripheral clinical manifestations or not) meet one of the following criteria: (1) Imaging shows sacroiliitis and has >= 1 feature of spondyloarthritis; (2) HLA-B27 positive and having >= 2 characteristics of spondyloarthritis. The characteristics of spondyloarthritis include: 1) Inflammatory low back pain; 2) Arthritis 3) Tendon attachment point inflammation (heel); 4) Uveitis 5) Finger (toe) inflammation 6) Psoriasis 7) Crohn's disease/Ulcerative colitis 8) NSAID treatment is effective; 9) Have a family history of spondyloarthritis; 10) HLA-B27 positive; 11) Elevated CRP.
Exclusion criteria
Exclusion criteria: If you meet any of the following criteria, you will not be enrolled in this study: 1 It cannot be combined with the detection of drug concentration and anti-antibodies during the research period. 2 Due to contraindications, they cannot be treated in accordance with the guidelines in a standardized manner, such as patients in the active stage of tuberculosis; 3 Within the last three months or currently participating in clinical trials; 4 There are situations where other researchers judged that it was not suitable to be included in the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BASDAI;ASDAS;Adalimumab drug concentration;Adalimumab antibody level;The drug concentration of Secukinumab;Secukinumab antibody level; | — |
Secondary
| Measure | Time frame |
|---|---|
| Erythrocyte sedimentation rate;C-reactive protein; | — |
Countries
China
Contacts
Public ContactJinxian Huang
Hong Kong University Shenzhen Hospital
Outcome results
None listed